Abstract: Novel wash and carrier solutions ideally suited for topical administration (e.g., as wash solutions and as carrier solutions). The solutions described herein are non-toxic, non-irritating, isotonic, possess non-specific broad-spectrum antimicrobial properties, and have an alkaline pH. Also disclosed are sterile preparations of the solutions and methods of using the same.

Abstract: Phase-separated elastomeric biocompatible polymer compositions are disclosed that are bioresorbable and/or biodegradable, and are useful in a variety of medical applications in which a low modulus polymer is desired, such as in the fabrication of medical devices.

Abstract: The present invention provides a base composition that allows for the formulation of non-irritating cosmetic and/or dermatological compositions. The base composition includes one or more of electrolyte, buffer, mild preservative, lubricant, or any combinations thereof. It is preferred that one or more of the above components are eye-safe and/or eye-compatible. The present invention also provides photoprotective cosmetic and/or dermatological compositions that include the base composition and one or more sunscreen active components and are non-irritating to mammalian eyes.

Abstract: A composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent is provided. A method of making a composition comprising an alloplastic injectable suspension for use as a dermal filler comprising a biocompatible and pliable material and a physiologically acceptable suspending agent, said method comprising admixing a biocompatible and pliable material with a physiologically acceptable suspending agent, is also provided. A method of augmenting soft tissue to provide long-term reduction of a skin defect, said method comprising stimulating collagen beneath the skin defect is further provided.

Abstract: Described herein are methods of inhibiting the activity of a virus or a bacterium comprising contacting a virus or bacterium with a polymer functionalized with at least one boronic acid moiety. Also described are methods of treatment using such functionalized polymers.

Abstract: An embodiment relates to a composition comprising a noble-metal containing nanoparticle and a polymer located on a surface of the nanoparticle, wherein the polymer is a polycondensation product of a halogenated monomer. Other embodiments relate to the method of making a composition and providing antimicrobial treatment using the composition.

Abstract: The invention relates generally to treatments of disordered bony structures, in particular to vertebroplasty compositions and methods and, more specifically, to treating vertebral bodies in living creatures, in particular, human beings and also compositions suitable for use in such methods and preparation and use of such compositions. According to the invention the composition to be used is an addition curable polysiloxane system.

Abstract: A formulation for generating an adhesion barrier that includes a plurality of particles or a dry powder that is made of a polymer combination of at least one biodegradable polymer and at least one water soluble polymer is disclosed. Methods of making and delivering the formulation are further disclosed. The formulation of particles is deposited on a surface of internal body tissue and the deposited formulation absorbs moisture from the tissue and forms a film over the surface. The film acts as an adhesion barrier by reducing or preventing adhesion of the surface to other body tissue.

Abstract: In one embodiment, a method of making a wound dressing comprises dissolving at least one hemostatic agent in at least one solvent to form a solution. The method continues by freeze drying the solution to form a sponge. The method further comprises including an enzyme in the sponge that enables a human body to readily degrade the hemostatic agent.

Abstract: The present invention relates to particles produced by drying aqueous dispersions of nanoureas and to methods for the production thereof.

Abstract: The present invention relates to elastic, hydrophilic and substantially spherical microspheres useful for dermal augmentation and tissue bulking. The invention provides injectable compositions comprising the microspheres and a biocompatible carrier for use in dermal augmentation. The present invention further provides methods of dermal augmentation and tissue bulking, particularly for the treatment of skin contour deficiencies, Gastro-esophageal reflux disease, urinary incontinence, and urinary reflux disease, using the injectable compositions.

Abstract: Use of the one or more oligomers of lactic acid with the following formula (I) wherein n is an integer from 2 to 25 such as, e.g., from 2 to 20, from 3 to 25, from 3 to 20, from 2 to 15, from 3 to 15, from 2 to 10, from 3 to 10, from 4 to 10, or from 4 to 9 or a lactic acid oligomeric product for the prophylaxis and/or treatment of a disease or condition that benefit of an acidic environment especially a gynaecological infection such as a bacterial infection, such as bacterial vaginosis, unspecific colpitis, senile colpitis, cervicitis, and urethritis, a fungal infection, such as candidosis (Candida albicans), cryptococcosis, actinomycosis, or a viral infection, such as Human Immunodefiency Virus (HIV), Herpes Simplex Virus (HSV), Human Papilloma Virus (HPV).

Abstract: The invention relates to a macromolecule comprising a polymer central core having at least two atoms to which at least two monomers are attached forming a dendrimeric structure comprising at least three polymer bonds, at least two linear polymers (b) being bond to said polymer bonds, wherein said polymers (b) at least have terminal functional groups for cytotoxic agents and at least on extended polymer (a) having a size of at least 1 carbon atoms longer than said polymers (b) and at least a terminal functional group for a targeting agent. The invention also relates to a macromolecule conjugate as well as a macromolecule biotin conjugate comprising said macromolecule, methods to produce said macromolecules as well as kits or system comprising said macromolecules and method of treating a mammal by said macromolecules.

Abstract: A medical antimicrobial composition includes a siloxanyl structure-containing polymer and an ammonium group-containing polymer, which is excellent in transparency, flexibility and mechanical properties, and also excellent in adhesion to a base resin with good mechanical properties, particularly to a silicone resin. The medical antimicrobial composition includes an ammonium group-containing polymer compound (A) dispersed in a siloxanyl structure-containing polymer (B) and a medical device comprising the medical antimicrobial composition.

Abstract: The present invention provides inventive polyol-based polymers, materials, pharmaceutical compositions, and methods of making and using the inventive polymers and materials. In certain aspects of the invention, an inventive polymer corresponds to a polymer depicted below. Exemplary inventive polymers includes those prepared using polyol units (e.g., xylitol, mannitol, sorbitol, or maltitol) condensed with polycarboxylic acid units (e.g., citric acid, glutaric acid, or sebacic acid). The inventive polymers may be further derivatized or modified. For example, the polymer may be made photocrosslinkable by adding methacrylate moieties to the polymer.

Abstract: Neutropenia-associated pneumonia is treated with a therapeutically effective amount of a small-molecule PTEN inhibitor. The method may further include detecting a resultant alleviation of the neutropenia-associated pneumonia, and/or diagnosing the neutropenia-associated pneumonia. The patient may be undergoing anti-cancer chemotherapy and/or radiotherapy, and the methods may further include the step of treating the patient with broad-spectrum antibiotic therapy or granulocyte colony-stimulating factor (G-CSF) therapy.

Abstract: This invention relates to sterilized cyanoacrylate adhesive compositions with x-ray imagining capabilities, methods of making such compositions, and methods of using such compositions.

Abstract: A method and a composition for making a composition, tablet, or tablet core having cross-linked polyallylamine salts such as sevelamer hydrochloride, sevelamer carbonate, or colesevelam hydrochloride, that may be used for treating hyperphosphatemia or reducing cholesterol. The method involves blending of a cross-linked polyallylamine salt with a water soluble excipient, optionally with water, an additive and/or a lubricant, and further tableting the resulting blend to form tablets and tablet cores.

Abstract: Polyphosphazene polymers having immunomodulating activity, and the biomedical use of such polyphosphazene polymers, in conjunction with an antigen or an immunogen are disclosed.

Abstract: Described herein are biocompatible compositions that contain a copolymer and a filler material. In particular, described herein are compositions that include a copolymer and a filler which may be a calcium salt. Also described herein are methods in which the compositions are used to attach soft tissue to bone.

Abstract: Embodiments of the invention include the treatment of amyloid oligomer toxicity by administering a membrane sealant co-polymer, for example poloxamer 188 (P188).

Abstract: The invention relates to a condensation product obtainable by reaction of a1) at least one bicyclic or polycyclic aromatic or heteroaromatic, where the bicyclic or polycyclic aromatic or heteroaromatic is substituted by at least one carboxyl group (—COOH), and where the carboxyl group can be present in salt form, a2) at least one carbonyl compound, a3) if appropriate at least one sulfonating agent, a4) at least one urea derivative, and a5) if appropriate at least one further aromatic or heteroaromatic, or a physiologically tolerable salt thereof.

Abstract: The invention relates to compositions comprising pholyphenol derivatives, characterised in that said polyphenols contain monomers, oligomers or polymers with units having formula (I), said units being characterised by the simultaneous presence of a resorcinol nucleus (nucleus A) and a para-phenol nucleus (nucleus B) which are interconnected by a carbon bond C, said derivatives being over-activated, in respect of the nucleophilic power thereof, by alkylation of at least one phenol function of each constituent monomer unit and stabilised by sterification by mixtures of fatty acids in proportions reflecting those of vegetable oils formed mainly by unsaturated fatty acids of all of the other phenol functions. The invention is suitable for use in cosmetics, dietetics and therapeutics.

Abstract: Conjugates comprising at least two active agents linked by a diglycolic acid or polyglycol diacid linker are disclosed. The invention also concerns oligomers and polymers of these conjugates and their use in therapeutic and industrial applications for localized, immediate or fast release delivery of an active agent, such as an anti-microbial, anti-infective, or antiseptic agent.

Abstract: The invention relates to the use of polymeric guanidinium hydroxides based on a diamine which contains oxyalkylene chains and/or alkylene groups between two amino groups, obtainable by polycondensation of a guanidine acid addition salt with the diamine, whereby a polycondensation product in the form of a salt is obtained, which subsequently is converted into the hydroxide form via basic anion exchange, for controlling microorganisms.

Abstract: The invention provides small molecule drugs that are chemically modified by covalent attachment of a water-soluble oligomer.

Abstract: A bio-adhesive supramacromolecular complex of the general formula: wherein R1 is independently selected from the group consisting of an alkane unsubstituted or substituted with alkoxy groups; R2 is independently selected from the group consisting of C1-6 alkyl; R3 and R4 are independently selected from the group consisting of optionally substituted aliphatic or aromatic alkyl; R5 is independently selected from the group consisting of H or C1-6 alkyl; W is a hydrogen-bond accepting functional group-containing entity; Y is a carboxylic acid ester or amide linkage; R is an independently selected peptide linking group; T1, T2, T3 and T4 are independently selected polymer residues; and m1, m2, m3, n1 and n2 are integers selected from at least 25; and wherein P has a molecular weight of about 1×103 to 1×107 and Q has a molecular weight of about 1×103 to 1×107. The complex provides controlled nitric oxide release over a longer period of time than prior art compounds in the locally delivery systems.

Abstract: The present invention provides for use of a composition comprising black tea flavonoids as a prebiotic and/or for the treatment or prevention of conditions associated with poor gut health or low immunity. The flavonoids comprise thearubigin in an amount of at least 82% by weight of the tea flavonoids. Also provided is an edible product comprising the black tea flavonoids.

Abstract: A hydrogel composition for application to vascular puncture site of an animal to arrest bleeding and promote hemostasis mixes a biocompatible, synthetic, electrophilic polymer component comprising a poly(ethylene glycol) (PEG) Succinimidyl Glutarate having a functionality of four and a molecular weight of about 10,000 g/mole, with a biocompatible, synthetic, nucleophilic polymer component comprising a blend of a poly(ethylene glycol) (PEG) Amine having a functionality of four and a molecular weight of about 10,000 g/mole, and a Poly-L-Lysine hydrobromide having a molecular weight of greater than about 8000 g/mole.

Abstract: Compounds exhibiting angiogenic properties incorporating the structure of Formula I: R3—NH—NH—C(?O)—R2—P—R1??(I) wherein P is a water-soluble, biodegradable polymer, R1 is hydrogen, lower alkyl, lower alkoxy or —R2—C(?O)—NH—NH—R3; each R2 is independently —CH2—, —NH— or O; and each R3 is independently hydrogen or a residue of a naturally occurring alpha-L-amino acid or dipeptide thereof. Polymer networks crosslinked with hydrazide compounds are also disclosed, together with implantable medical devices incorporating the compounds and crosslinked polymers, and angiogenesis-promoting treatment methods, including wound-treatment methods.

Abstract: To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be preformed by directly contacting the agent with the nerve tissue at the site of the injury. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusion agent to the patient. The administration is preferably by parenteral administration including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tissue injury.

Abstract: A polymeric prodrug is described which comprises at least one polymer attached via at least one permanent bond to a bicine linker. The bicine linker is attached via a temporary linkage to an amine containing biologically active moiety. The amine containing biologically active moiety—such as a drug—can be released by cleaving the temporary linkage.

Abstract: Described herein are polymer-agent conjugates and particles, which can be used, for example, in the treatment of cancer or neurological deficits. Also described herein are mixtures, compositions and dosage forms containing the particles, methods of using the particles (e.g., to treat a disorder), kits including the polymer-agent conjugates and particles, methods of making the polymer-agent conjugates and particles, methods of storing the particles and methods of analyzing the particles.

Abstract: The present invention is related to an intravaginal delivery system for the controlled release of drospirenone and an estrogen, optionally also comprising one or more therapeutically active or a health-promoting substance capable of giving and/or enhancing protection against bacterial and fungal infections, and/or enhancing protection against sexually transmitted diseases. The delivery system consists of one or more compartments, one of each comprising a core and a membrane encasing the core, said core and membrane essentially consisting of a same or different polymer composition, wherein at least one compartment comprises drospirenone ant at least one compartment which may be the same or different from the one comprising drospirenone, comprises an estrogen or a mixture of drospirenone and an estrogen, and wherein the membrane or the surface of the membrane or at least one of the cores comprises said therapeutically active or a health-promoting substance.

Abstract: A method of producing bronchorelaxation in the lungs of a human or animal affected by airway obstruction comprises administration of a pharmacologically effective amount to the body or to the intestine of said human or animal of an agent capable of binding mercury in elemental, ionic and/or organic form present in the body or in the intestinal lumen to enhance its excretion via the feces and/or the urine. A corresponding use of the agent and its use for the manufacture of a medicament are also disclosed.

Abstract: This invention relates to thermoplastic elastomers comprising at least one silicone ionomer. These thermoplastic elastomers may be reprocessed and/or recycled.

Abstract: A polymerizable cholesteric liquid crystal composition in the invention includes at least one compound selected from the group consisting of a polymerizable ester compound (1) having a residue of a hydrolysate of ?-oryzanol (A) and having a ring structure, a polymerizable ester compound (2) having a residue of a hydrolysate of ?-oryzanol (A) and having no ring structures, and a polymerizable ester compound (3) having a residue of a hydrogenated product of ?-oryzanol.

Abstract: Polymers derived directly from acrolein monomer that are substantially soluble in water and/or aqueous media, together with methods for preparing same and compositions containing such for use as an anti-microbial, anti-cancer, anti-inflammatory and/or anti-coagulant.

Abstract: A microbicidal delivery system including: a microbicidal composition including a microbicidal compound including a dendrimer including one or more surface groups of formula (IV); a microbicidally active derivative thereof, or pharmaceutically acceptable salt or solvate thereof; and a carrier, excipient or diluent therefor; and a prophylactic device; the microbicidal composition being carried on a surface of the prophylactic device and being compatible therewith.

Abstract: A composition comprising a structural component comprising linear acrylic homopolymers or linear acrylic copolymers and a biobeneficial component comprising copolymers having an acrylate moiety and a biobeneficial moiety is disclosed. A medical article comprising the composition in the coating thereof and a method of fabricating the medical article are also disclosed.

Abstract: A drug-releasing polyelectrolyte coating includes: (a) at least two oppositely charged polyelectrolyte layers; (b) at least one pharmaceutical active drug which is covalently coupled to polyelectrolytes of at least one of the polyelectrolyte layers; (c) wherein the drug exhibits a release rate from the polyelectrolyte coating of less than 50% in 3 days.

Abstract: Embodiments of the present subject matter provide a biocidal composition comprising an aqueous mixture of (a) a phosphonium compound and (b) a polymeric ammonium compound, wherein the weight ratio of compound (a) to compound (b) is from 0.2:1 to 20:1, and wherein the phosphonium compound (a) has formula: wherein each R is independently a C1-C6 alkyl group which is unsubstituted or substituted by a cyano, hydroxyl, esterified hydroxyl or aryl group; R1 represents a C8-C18 alkyl group which is substituted or unsubstituted; and X represents either chlorine or bromine; and wherein the polymeric ammonium compound (b) comprises the repeat unit: wherein each R2 is independently a C1-C2 alkyl group which is substituted or unsubstituted; R3 represents a C2-C18 alkyl or alkenyl group which is substituted or unsubstituted; and R4 represents a C2-C18 alkyl or alkenyl group which is substituted or unsubstituted, a diethyl ether group, an isopropanol group,a N,N-dipropylurea group, or a 2-butene group.

Abstract: A C-nitroso moiety derived from a carbon acid with a pKa less than about 25 is bound in a biocompatible polymer as an ester or ether to a pendant hydroxyl group, as an ester to a pendant carboxylic acid or as an amine or amide to a pendant amine moiety. The polymer with c-nitroso moiety bound thereto can be coated on a medical device and/or used for prophylaxis of a patient at risk for restenosis. A c-nitroso moiety bound as amide to polyisobutylene amine substituted styrene copolymer is described in detail.

Abstract: Provided herein are compositions and methods for preventing and treating diseases and risk factors associated with metabolic syndrome by targeting the RGD-binding site of selected intra- and extracellular proteins. Exemplary compositions include RGD-polyphenol conjugates via an ester linkage; polyphenol polymer conjugated to RGD analogs or mimetics; and RGD polymer conjugates linked to polyphenol.

Abstract: Absorbable polyurethanes, polyamides and polyester urethanes prepared from at least one compound selected from: or the diamines and diisocyanates thereof, wherein each X represents a member independently selected from —CH2COO— (glycolic acid moiety), —CH(CH3)COO— (lactic acid moiety), —CH2CH2OCH2COO— (dioxanone), —CH2CH2CH2CH2CH2COO— (caprolactone moiety), —(CH2)yCOO— where y is one of the numbers 2, 3, 4 or 6-24 inclusive, and —(CH2CH2O)z?CH2COO— where z? is an integer between 2 and 24, inclusive; each Y represents a member independently selected from —COCH2O— (glycolic ester moiety), —COCH(CH3)O— (lactic ester moiety), —COCH2OCH2CH2O— (dioxanone ester), —COCH2CH2CH2CH2CH2O— (caprolactone ester), —CO(CH2)mO— where m is an integer between 2, 3, 4 or 6-24 inclusive, —COCH2O(CH2CH2O)n— where n is an integer between 2 and 24, inclusive; R? is hydrogen, benzyl or an alkyl group, the alkyl group being either straight-chained or branched; p is an integer between 1 and 4, inclusive; and Rn represents one or more

Abstract: The current invention relates to an implantable medical device made of semi-crystalline poly(ester amide) (PEA) polymer.

Abstract: It is intended to provide a remedy for diseases caused by macrophages with dysfunction or mediated by macrophages. Namely, a remedy which activates the phagocytic capacity of macrophages and thus is efficiently incorporated into the macrophages due to the vigorous phagocytosis. As a result, the macrophages with dysfunction are normalized, macrophages infected with a pathogen are exterminated or a pathogen in the infected macrophages is exterminated.

Abstract: Amide compounds, amide polymers and compositions, including amide compounds and amide polymers, may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, the amide polymers may be amido-amine dendrimers that may be formed via a series of iterative reactions.

Abstract: An amide of hyaluronic acid or a derivative thereof which comprises at least one repetitive unit of general formula (1).: wherein R?NR6R7, or alcoholic group of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, OH, O—, alcoholic group of hyaluronic acid, amino group of deacylated hyaluronic acid; R1, R2, R3, R4?H, SO3—, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, —CO—(CH2)2—COOY; Y=negative charge, or H; R5?—CO—CH3, H, SO3—, acyl group derived from a carboxylic acid of the aliphatic, aromatic, arylaliphatic, cycloaliphatic, heterocyclic series, acylic group of hyaluronic acid; R6=is H or a aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted; R7=is H or an aliphatic, aromatic, arylaliphatic, cycloaliphatic, or heterocyclic group, substituted or unsubstituted; wherein at least one of R or R5 forms an amide group.

Abstract: Disclosed are polyquaternary ammonium polymers containing polyalkylene oxide groups according to formula (I) wherein [A]x, [B]y and [C]z are poly(alkylene oxides) each independently selected from the group consisting of poly(ethylene oxide), poly(propylene oxide), and poly(butylene oxide); Z is selected from the group consisting of —CH2CH?CHCH2—, —CH2CH2CH2CH2—, —CH2—C?C—CH2—, —CH2CH2—O—CH2CH2—, —CH2—N(CH2CH2)2N—CH2—, —CH2CH(OH)CH(OH)CH2— and —CH2—C6H4—CH2—; R is —(CR1R2)mCR3R4— wherein m is an integer from 0 to 3 and R1, R2, R3 and R4 are independently selected from the group consisting of H, CH3 and CH2CH3; n is an integer from 1 to 30; x is either 0 or an integer from 2 to 20; y is an integer from 2 to 20; z is either 0 or an integer from 2 to 20; R? is a branched or unbranched alkyl group having from 1 to 3 carbon atoms and is optionally substituted by one or two hydroxyl groups; Q1 and Q2 are independently selected from the group consisting of —CH2CH?CHCH2—X, —CH2C?C—CH2—X, —N(R?)2, —N(R?)3, —N(R?)(R?),